Welcome to our dedicated page for NYXOAH S A news (Ticker: NYXH), a resource for investors and traders seeking the latest updates and insights on NYXOAH S A stock.
Nyxoah SA reports medical-technology developments tied to the Genio system, its patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for obstructive sleep apnea. Company news commonly covers financial and operating results, U.S. commercialization activity, regulatory status, manufacturing capacity, reimbursement references, investor conference participation, and the development and commercialization of OSA treatment alternatives.
Nyxoah also publishes regulated information for its Euronext Brussels and Nasdaq securities, including transparency notifications, shareholder-meeting materials, voting-right disclosures, and bond-related capital-structure notices.
Nyxoah SA, a medical technology company, announced on July 14, 2021, it received a transparency notification from Deerfield Partners, L.P. The notification, received on July 12, detailed that Deerfield acquired 899,300 shares on July 7, 2021, crossing the 3% voting rights threshold, now holding 3.60% of the total voting rights. This acquisition reflects Deerfield’s growing investment in Nyxoah, indicating confidence in the company’s future prospects.
Nyxoah SA announced the issuance of 435,250 new shares on July 9, 2021, following a capital increase tied to its IPO in the U.S. and the exercise of subscription rights. The total share capital now stands at EUR 4,369,902.59, resulting in 25,437,859 voting rights from ordinary shares. Additionally, there are outstanding rights to subscribe to 927,500 shares through various ESOP warrants.
Nyxoah announced the closing of its initial public offering (IPO) on July 7, 2021. The offering included 2,835,000 ordinary shares priced at $30 per share, accumulating total gross proceeds of $85.1 million. Furthermore, underwriters exercised their option to purchase an additional 425,250 shares, increasing gross proceeds to $97.8 million. The closing of this additional share purchase is anticipated on July 9, 2021, subject to standard conditions. Piper Sandler, Stifel, and Cantor acted as joint book-running managers for this offering.
Nyxoah announced the issuance of 2,835,000 new shares on July 7, 2021, related to a capital increase tied to its initial public offering in the United States. This means the share capital now stands at EUR 4,295,126.64, with a total of 25,002,609 voting rights available. The press release outlines the total number of securities and shares following this increase, including various ESOP Warrants that allow holders to subscribe to additional voting securities.
Nyxoah SA has priced its initial public offering (IPO) in the U.S. at US$ 30 per share, totaling US$ 85.1 million in gross proceeds. The offering includes 2,835,000 ordinary shares, with an option for underwriters to purchase an additional 425,250 shares. The IPO is set to close on July 7, 2021, pending conditions. The shares will begin trading on NASDAQ under the symbol NYXH. This marks a significant step in Nyxoah's mission to develop innovative solutions for Obstructive Sleep Apnea.
Nyxoah SA (Euronext Brussels: NYXH) announced the issuance of 60,000 new shares on June 23, 2021, due to the exercise of subscription rights. The company's capital is now EUR 3,808,073.64. The total number of voting rights is 22,167,609, all of which are ordinary shares. Furthermore, various warrants, including 91 from 2013, 365 from 2016, 319 from 2018, and 550,000 from 2020, provide additional rights to subscribe to further shares.